Stocks Health care LMAT
NASDAQ · Health careLemaitre Vascular Inc (LMAT)
Lemaitre Vascular Inc brought in $269.4M of revenue over the twelve months to September 30, 2026, up 11.8% from a year earlier. Net income was $63.3M, a net margin of 23.5%. Operating cash flow minus capital spending left $74.5M of free cash flow in fiscal 2025. At September 30, 2026 it held $27.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Lemaitre Vascular Inc
- Net worth
- Lemaitre Vascular Inc has a market value (market cap) of $1.8B at the latest share price, and shareholders' equity of $432.1M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $249.6M (+13.5% year on year), with net income of $57.7M. Over the 12 months to September 30, 2026: revenue $269.4M, net income $63.3M.
- Cash flow
- In fiscal 2025 operations brought in $81.3M of cash; after $6.8M of capital spending, free cash flow was $74.5M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Lemaitre Vascular Inc's next report is expected around February 24, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
- Dividend
- Lemaitre Vascular Inc declared dividends of $0.80 per share in fiscal 2025, a yield of 1.01% at the current price.
What Lemaitre Vascular Inc does
Lemaitre Vascular Inc is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker LMAT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $249.6M | $57.7M | $2.52 | $74.5M |
| 2024 | $219.9M | $44M | $1.93 | $37.2M |
| 2023 | $193.5M | $30.1M | $1.34 | $29.5M |
| 2022 | $161.7M | $20.6M | $0.93 | $22.1M |
| 2021 | $154.4M | $26.9M | $1.25 | $30.2M |
| 2020 | $129.4M | $21.2M | $1.04 | $31.8M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where LMAT ranks in Health care
Dividends
Lemaitre Vascular Inc declared $0.80 per share in fiscal 2025. At the current price that is a yield of 1.01%. It paid out $18.1M in cash dividends, 31% of its net income.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2025 | $0.80 | $18.1M | 31% |
| 2024 | $0.64 | $14.4M | 33% |
| 2023 | $0.56 | $12.4M | 41% |
| 2022 | $0.50 | $11M | 53% |
| 2021 | $0.44 | $9.3M | 35% |
| 2020 | $0.38 | $7.7M | 36% |
Latest SEC filings
What Lemaitre Vascular Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 11% to $68M versus the same quarter last year; diluted EPS $0.65 versus $0.75.
- November 4, 2026
- October 15, 2026
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 9.6% to $70.4M versus the same quarter last year; diluted EPS $0.74 versus $0.60.
- August 4, 2026
- July 27, 2026Passive stake (5% or more) SCHEDULE 13G
- June 5, 2026
- May 29, 2026
- May 14, 2026Passive stake changed SCHEDULE 13G/A
- May 6, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 11% to $66.6M versus the same quarter last year; diluted EPS $0.68 versus $0.48.
What is LMAT worth? A DCF from its reported cash flow
Insider trades
What the people running Lemaitre Vascular Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 1 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 1, 2026 | Roush John ADirector | Exercised options | 3,444 | $167.4K |
| June 4, 2026 | LeMaitre George WChairman and CEO, Director | Gave as a gift | 11,974 | - |
| June 4, 2026 | LeMaitre George WChairman and CEO, Director | Received as payindirect | 11,974 | - |
| May 8, 2026 | Kamke Trent GSenior V. P., Operations | Sold | 2,928 | $313.3K |
| May 8, 2026 | LeMaitre George WChairman and CEO, Director | Sold | 27,881 | $3M |
| May 7, 2026 | Jasinski Lawrence JDirector | Exercised options | 1,069 | $50.4K |
| May 7, 2026 | Jasinski Lawrence JDirector | Exercised options | 924 | $50.5K |
| May 7, 2026 | Jasinski Lawrence JDirector | Exercised options | 865 | $87.5K |
Who owns LMAT
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Conestoga Capital Advisors13G, passive | 8.12% | January 9, 2026 |
| George W. LeMaitre13G, passive | 6.4% | May 14, 2026 |
| Copeland Capital Management13G, passive | 5.21% | January 24, 2025 |
| First Trust Portfolios L.P.13G, passive with 2 related filers | 5.15% | July 27, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 326 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 3,272,973 | +128,822 |
| Conestoga Capital Advisors, LLC | 1,367,513 | -109,300 |
| First Trust Advisors LP | 1,093,502 | +95,431 |
| Congress Asset Management Co | 963,706 | +129,177 |
| Vanguard Capital Management LLC | 953,437 | +41,379 |
| State Street Corp | 901,416 | +45,632 |
| Copeland Capital Management, LLC | 839,463 | -31,229 |
| Geode Capital Management, LLC | 788,835 | +130,390 |
| Vanguard Portfolio Management LLC | 604,833 | +42,063 |
| Geneva Capital Management LLC | 589,064 | -164,928 |
| Dimensional Fund Advisors LP | 493,889 | +17,554 |
| Goldman Sachs Group Inc | 473,194 | +40,778 |
| Invesco Ltd. | 448,389 | +114,412 |
| Morgan Stanley | 351,083 | -56,688 |
| Northern Trust Corp | 333,325 | +20,770 |
| Two Sigma Investments, LP | 316,528 | +34,550 |
| Royal Bank of Canada | 308,765 | +36,111 |
| Annex Advisory Services, LLC | 248,253 | -2,357 |
| UBS Group AG | 247,804 | +206,387 |
| Envestnet Asset Management Inc | 244,729 | -29,667 |
Insiders
10 insiders reported holding 1,580,989 shares in total, about $124.9M at the last price.
| Holder | Shares |
|---|---|
| LeMaitre George WChairman and CEO, Director | 1,463,41945,374 held indirectly |
| O'Connor John JamesDirector | 62,827 |
| Pellegrino Joseph P JRDirector | 15,021 |
| Roberts David BPresident and Director, Director | 14,667 |
| Roush John ADirector | 7,386 |
| Jasinski Lawrence JDirector | 4,714 |
| Ross Bridget ADirector | 3,942 |
| Kamke Trent GSenior V. P., Operations | 3,749 |
| Shadan MarthaDirector | 2,962 |
| LeBlanc Dorian PaulChief Financial Officer | 2,302 |
Questions about LMAT
What does Lemaitre Vascular Inc do?
Lemaitre Vascular Inc is a company in the Health care sector, listed on NASDAQ as LMAT. Its shares trade on NASDAQ under the ticker LMAT.
What is Lemaitre Vascular Inc's net worth?
Lemaitre Vascular Inc has a market value (market cap) of $1.8B at the latest share price, and shareholders' equity of $432.1M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Lemaitre Vascular Inc profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $63.3M on revenue of $269.4M, a net margin of 23.5%.
How much revenue does Lemaitre Vascular Inc make?
Over the twelve months to September 30, 2026 Lemaitre Vascular Inc reported revenue of $269.4M. That is 11.8% more than a year earlier.
When did Lemaitre Vascular Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026.
When is Lemaitre Vascular Inc's next earnings report?
Lemaitre Vascular Inc's next report is expected around February 24, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Does Lemaitre Vascular Inc pay a dividend?
Yes. Lemaitre Vascular Inc declared dividends of $0.80 per share in fiscal 2025, a yield of 1.01% at the current price.
Similar companies
Compare LMAT with
Follow LMAT
Get an email when Lemaitre Vascular Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Lemaitre Vascular Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.